Effect of OXSIGHT Smart Glasses on Patients With Advanced Glaucoma (NCT04434612) | Clinical Trial Compass
UnknownNot Applicable
Effect of OXSIGHT Smart Glasses on Patients With Advanced Glaucoma
30 participantsStarted 2020-06-06
Plain-language summary
Glaucoma is the leading cause of irreversible blindness worldwide. The visual function of patients with advanced glaucoma is severely impaired, and the vision-related activities (e.g. movement, reading) are obviously restricted, which may have a negative impact on the patients' quality of life (QOL) and increase the burden on individuals and families. Low vision aids (LVAs) and other devices for vision rehabilitation (VR) are useful for patients with advanced glaucoma to maximize the function of residual vision and improve the QOL. OXSIGHT smart glasses are the latest LVAs eyeglasses that are expected to improve the QOL for patients with low vision (LV), such as those with glaucoma. Clinical data were collected to evaluate the efficacy and its influencing factors of OXSIGHT smart glasses in patients with advanced glaucoma, in providing theoretical basis for subsequent clinical studies.
Who can participate
Age range
10 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. age ≥10 years, able to complete all tests and inspections;
. a definite diagnosis of primary or secondary glaucoma or glaucoma in children;
. the best corrected visual acuity of the better eye is no more than 0.3 and better than 0.05; visual field ≤10° and MD value \< -12db;
. Visual acuity, intraocular pressure, and other eye conditions have been stable for more than 6 months.
Exclusion criteria
. unable to cooperate with related inspections;
. a history of eye surgery or eye laser within 6 months;
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Changes from baseline CLVQOL scores at different time points
Timeframe: The examination was performed at 1 day, 1 week, 2 weeks, 4 weeks and 8 weeks after intervention.
Trial details
NCT IDNCT04434612
SponsorZhongshan Ophthalmic Center, Sun Yat-sen University
. diseases that interfere with the diagnosis of glaucoma, such as optic disc dysplasia, obvious anisometropia, retinal vascular diseases, optic nerve diseases, macular degeneration, cerebrovascular diseases, etc.;
. pregnant or lactating women;
. those who refuse to sign the informed consent or voluntarily withdraw from the study due to discomfort or other reasons.